

# Berberine: New Research on Mechanisms Via Which This Alkaloid May Impact Metabolic and Cardiovascular Health

by Carrie Decker, ND

## References

1. Matthews HB, Lucier GW, Fisher KD. Medicinal herbs in the United States: research needs. *Environ Health Perspect.* 1999 Oct;107(10):773-8.
2. Dattner AM. From medical herbalism to phytotherapy in dermatology: back to the future. *Dermatol Ther.* 2003;16(2):106-13.
3. Wong M. *La médecine chinoise par les plantes.* Paris: Editions Tchou; 1976.
4. Jin JL, et al. Antibacterial mechanisms of berberine and reasons for little resistance of bacteria. *Chin Herb Med.* 2010;3:27-35.
5. Sun D, et al. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic *Escherichia coli.* *Antimicrob Agents Chemother.* 1988 Aug;32(8):1274-7.
6. Gu L, et al. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxemia. *J Infect Dis.* 2011 Jun 1;203(11):1602-12.
7. Li N, et al. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. *Eur J Pharm Sci.* 2010 Apr 16;40(1):1-8.
8. Chen DP, et al. Effects of berberine on rat jejunal motility. *J Pharm Pharmacol.* 2013 May;65(5):734-44.
9. Feng Y, et al. Inhibiting roles of berberine in gut movement of rodents are related to activation of the endogenous opioid system. *Phytother Res.* 2013 Oct;27(10):1564-71.
10. Tang QL, et al. Antinociceptive effect of berberine on visceral hypersensitivity in rats. *World J Gastroenterol.* 2013 Jul 28;19(28):4582-9.
11. Wang Y, et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. *Metabolism.* 2017 May;70:72-84.
12. Stilling RM, et al. The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? *Neurochem Int.* 2016 Oct;99:110-132.
13. Pan GY, et al. The involvement of P-glycoprotein in berberine absorption. *Pharmacol Toxicol.* 2002 Oct;91(4):193-7.
14. Feng R, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. *Sci Rep.* 2015 Jul 15;5:12155.
15. Wu X, et al. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. *Eur J Clin Pharmacol.* 2005 Sep;61(8):567-72.
16. Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. *Eur J Clin Pharmacol.* 2012 Feb;68(2):213-7.
17. Derrien M, et al. *Akkermansia muciniphila* gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. *Int J Syst Evol Microbiol.* 2004 Sep;54(Pt 5):1469-76.
18. Escobar JS, et al. The gut microbiota of Colombians differs from that of Americans, Europeans and Asians. *BMC Microbiol.* 2014 Dec 14;14:311.
19. Dao MC, et al. *Akkermansia muciniphila* and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. *Gut.* 2016 Mar;65(3):426-36.
20. Clarke SF, et al. Exercise and associated dietary extremes impact on gut microbial diversity. *Gut.* 2014 Dec;63(12):1913-20.
21. Zhao S, et al. *Akkermansia muciniphila* improves metabolic profiles by reducing inflammation in chow diet-fed mice. *J Mol Endocrinol.* 2017 Jan;58(1):1-14.
22. Everard A, et al. Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci U S A.* 2013 May 28;110(22):9066-71.
23. Li J, et al. *Akkermansia muciniphila* protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in ApoE<sup>-/-</sup> mice. *Circulation.* 2016;133:2434-2446.
24. Shin NR, et al. An increase in the *Akkermansia* spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. *Gut.* 2014 May;63(5):727-35.
25. Zhu L, et al. Berberine treatment increases *Akkermansia* in the gut and improves high-fat diet-induced atherosclerosis in ApoE<sup>-/-</sup> mice. *Atherosclerosis.* 2018 Jan;268:117-126.
26. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. *J Am Coll Cardiol.* 1999 Sep;34(3):631-8.
27. Paradisi G, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. *Circulation.* 2001 Mar

- 13;103(10):1410-5.
28. Tietjen GE, et al. Migraine and biomarkers of endothelial activation in young women. *Stroke*. 2009 Sep;40(9):2977-82.
29. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. *Clin Sci (Lond)*. 2005 Aug;109(2):143-59.
30. Shimabukuro M, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. *J Clin Endocrinol Metab*. 2003 Jul;88(7):3236-40.
31. Viollet B, et al. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. *Diabetes Metab*. 2007 Dec;33(6):395-402.
32. Brusq JM, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. *J Lipid Res*. 2006 Jun;47(6):1281-8.
33. Salt IP, et al. AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System. *Circ Res*. 2017 May 26;120(11):1825-1841.
34. García-Prieto CF, et al. High-fat diet induces endothelial dysfunction through a down-regulation of the endothelial AMPK-PI3K-Akt-eNOS pathway. *Mol Nutr Food Res*. 2015 Mar;59(3):520-32.
35. Wang Y, et al. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. *Cardiovasc Res*. 2009 Jun 1;82(3):484-92.
36. Jeong HW, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. *Am J Physiol Endocrinol Metab*. 2009 Apr;296(4):E955-64.
37. Liang KW, et al. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. *Eur J Pharmacol*. 2008 Aug 20;590(1-3):343-54.
38. Wang J, et al. Berberine via suppression of transient receptor potential vanilloid 4 channel improves vascular stiffness in mice. *J Cell Mol Med*. 2015 Nov;19(11):2607-16.
39. Ko WH, et al. Vasorelaxant and antiproliferative effects of berberine. *Eur J Pharmacol*. 2000 Jul 7;399(2-3):187-96.
40. Wang X, et al. Identification of berberine as a direct thrombin inhibitor from traditional Chinese medicine through structural, functional and binding studies. *Sci Rep*. 2017 Mar 9;7:44040.
41. Zhou XQ, et al. Neuroprotective effects of berberine on stroke models in vitro and in vivo. *Neurosci Lett*. 2008 Dec 5;447(1):31-6.
42. Kim WS, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. *Am J Physiol Endocrinol Metab*. 2009 Apr;296(4):E812-9.
43. Zhang Y, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. *J Clin Endocrinol Metab*. 2008 Jul;93(7):2559-65.
44. Li XY, et al. Effect of berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. *J Transl Med*. 2015;13:278.
45. Wang Y, et al. Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. *Atherosclerosis*. 2010;209:111-7.
46. Briand F, et al. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. *Arterioscler Thromb Vasc Biol*. 2013 Jan;33(1):13-23.
47. Wang Y, et al. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. *Metabolism*. 2014 Sep;63(9):1167-77.
48. Sun R, et al. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. *Mol Pharmacol*. 2017 Feb;91(2):110-122.
49. Wu N, et al. Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia. *Am J Physiol Regul Integr Comp Physiol*. 2011 Mar;300(3):R635-43.